Published on

Clinical Toxicology — Psoralens

1. Overview

Psoralens are naturally occurring or pharmaceutical photosensitizing compounds belonging to the furocoumarin family. They increase the sensitivity of skin and other tissues to ultraviolet A (UVA) radiation.

Clinically important exposure occurs in two main settings:

  • Medication-related exposure: Oral or topical psoralens used in conjunction with UVA light during photochemotherapy.
  • Plant-related exposure: Contact with psoralen-containing plant sap, fruit juice, or other botanical preparations followed by sunlight exposure.

The defining toxic effect is phototoxic tissue injury. Exposure to psoralens without subsequent UVA irradiation may produce little immediate toxicity, whereas exposure to both can cause painful erythema, edema, blistering, and extensive burns.

The reaction is often delayed. Skin changes may not become apparent until 24–48 hours after UVA exposure and can continue to worsen over the next day.

Most cases resolve with light avoidance and supportive skin care. Severe phototoxic burns may require specialized wound management or hospitalization.

There is no specific antidote.

The central treatment principle is prevention of additional UVA exposure, including sunlight that passes through window glass.

2. Important psoralen compounds

Methoxsalen

Other names: 8-methoxypsoralen, 8-MOP, xanthotoxin.

Methoxsalen is the best-characterized pharmaceutical psoralen.

It is used with controlled UVA irradiation in a treatment called PUVA photochemotherapy.

Oral methoxsalen has been used for severe psoriasis, while psoralen-based therapy may also be considered for selected other dermatologic conditions.

Some specialized treatments use topical or bath-applied psoralens.

Trioxsalen

Other names: 4,5′,8-trimethylpsoralen, TMP.

Trioxsalen has historically been used for PUVA treatment, including vitiligo.

Availability and clinical use vary by country. It should not be assumed to be a routinely available or preferred contemporary oral treatment.

Bergapten

Other name: 5-methoxypsoralen, 5-MOP.

Bergapten occurs naturally in certain plants and has also been used in specialized photochemotherapy.

Natural furocoumarins

Plants may contain mixtures of psoralen-related compounds.

The clinical phototoxicity of a plant preparation depends on which compounds are present, their concentration, the quantity contacting the skin, and subsequent UVA exposure.


3. Therapeutic uses and PUVA photochemotherapy

PUVA stands for psoralen plus ultraviolet A.

In controlled treatment, a psoralen is administered orally, topically, or through a bath preparation before the patient receives a carefully measured UVA exposure.

PUVA may be used for selected cases of:

  • Psoriasis.
  • Vitiligo.
  • Cutaneous T-cell lymphoma.
  • Chronic eczema or other inflammatory skin conditions.
  • Certain photodermatoses.

Contemporary position

PUVA remains useful in selected dermatologic disorders but is less commonly chosen for routine psoriasis treatment where safer or more convenient alternatives, such as narrowband UVB phototherapy or systemic medications, are suitable.

Methoxsalen timing

The timing of oral methoxsalen administration depends on the formulation.

Certain rapid-absorption formulations are administered approximately 1.5–2 hours before UVA treatment.

Different formulations can have different absorption and photosensitivity profiles and should not be interchanged without adjusting the phototherapy regimen.

Clinical safety

Therapeutic UVA exposure must be determined by trained clinicians using an established treatment protocol.

Unsupervised oral psoralen use followed by sunlight exposure is unsafe.


4. Natural sources and phytophotodermatitis

Phototoxic furocoumarins are found in certain plants, particularly members of the Rutaceae, Apiaceae, and Moraceae families.

Source

Typical exposure

Lime and certain other citrus fruits

Juice or peel oil on skin followed by sunlight

Fig tree, Ficus carica

Sap or leaves contacting skin

Celery

Plant handling or concentrated plant products

Parsnip

Contact with stems, leaves, or sap

Parsley

Occupational or unusually concentrated exposure

Giant hogweed

Sap contacting skin

Cow parsnip and related plants

Outdoor plant handling

Bergamot oil

Selected cosmetics or fragrances

Not every food or plant in these botanical groups contains equally important quantities of phototoxic furocoumarins.

Lime-associated phototoxicity

A familiar presentation occurs when lime juice contacts the hands during outdoor food or drink preparation.

After sunlight exposure, the skin may develop irregular, drip-shaped, or handprint-like lesions.

This is sometimes called margarita photodermatitis.

Fig-associated injury

Fig sap and certain leaf preparations may produce significant phototoxic burns.

Applying crushed fig leaves or sap to skin as a home remedy is particularly hazardous when followed by sunlight exposure.

Giant hogweed

Giant hogweed sap can cause severe phototoxic skin injury, sometimes involving large areas.

Eye exposure also requires urgent assessment.

Important distinction

Phytophotodermatitis is generally phototoxic rather than allergic. A sufficient combination of furocoumarin exposure and UVA radiation can injure skin even without prior sensitization.


5. Mechanism of toxicity

Psoralens can enter cells and associate with DNA.

When activated by UVA radiation, they may form covalent bonds with DNA, including DNA cross-links.

These reactions interfere with DNA replication and contribute to cellular injury.

Photochemical reactions can also generate reactive oxygen species and damage cellular membranes and proteins.

Phototoxic inflammation

The resulting cellular injury triggers an inflammatory response.

Manifestations include erythema, swelling, pain, and blister formation.

Dose dependence

The severity of injury depends on both psoralen exposure and the amount of UVA radiation reaching the tissue.

Factors that increase risk include:

  • Greater psoralen concentration.
  • Excessive UVA exposure.
  • Fair skin or increased photosensitivity.
  • Simultaneous exposure to other photosensitizing agents.
  • Failure to protect treated areas.
  • Repeated irradiation before a previous reaction becomes apparent.

Important correction

Psoralen toxicity is not limited to direct DNA binding. Oxidative injury and other photochemical mechanisms also contribute.


6. Toxic dose and risk factors

There is no validated universal toxic dose for oral or topical psoralens.

A dose used safely with controlled dermatologic phototherapy may produce severe skin injury if followed by excessive or unplanned sunlight exposure.

Oral ingestion

Nausea and other gastrointestinal symptoms may occur without UVA exposure.

The principal concern after significant ingestion is subsequent generalized photosensitivity.

Topical exposure

A relatively localized exposure to concentrated plant sap or topical psoralen can cause extensive blistering if the affected skin receives sufficient UVA.

Other risk factors

Preexisting photosensitive disorders, abnormal pigmentation, other photosensitizing medications, and inaccurate phototherapy dosing can increase the risk of injury.

Clinical implication

The quantity of psoralen alone does not reliably predict the severity of poisoning without knowing the subsequent UVA exposure.


7. Clinical manifestations

Gastrointestinal effects

Oral methoxsalen may cause nausea, sometimes accompanied by vomiting or abdominal discomfort.

The symptoms are usually mild.

Early cutaneous findings

After UVA activation, patients may develop burning discomfort, tenderness, erythema, and edema.

Delayed phototoxic burns

More severe injury may produce:

  • Marked redness.
  • Painful swelling.
  • Vesicles or large bullae.
  • Skin erosion.
  • Occasionally ulceration.

The affected skin may resemble a severe sunburn.

Distribution

Systemic oral psoralen exposure can produce widespread photosensitivity in exposed skin.

Topical plant exposure typically causes localized or patterned lesions corresponding to the sites of contact and sunlight exposure.

Linear streaks, splashes, fingerprints, and sharply demarcated areas are characteristic clues.

Pigment changes

Postinflammatory hyperpigmentation is common.

It may persist for months and, in some cases, considerably longer.

Eye effects

Psoralens increase the vulnerability of ocular tissues to UVA injury.

Eye protection is therefore essential during and after oral PUVA treatment.

Long-term concern includes lens injury and cataract formation when appropriate precautions are not followed.

Severe complications

Extensive burns can cause pain, fluid losses, secondary infection, and substantial temporary disability.

Permanent scarring is possible in severe cases, although most uncomplicated lesions heal without significant structural damage.


8. Onset and clinical course

The time course differs from an ordinary thermal burn.

Time from exposure

Possible findings

Shortly after ingestion

Nausea or no symptoms

Following UVA exposure

Photochemical injury begins, often without immediate visible changes

Approximately 24–48 hours

Erythema, pain, swelling, and developing blisters

Approximately 48–72 hours

Peak phototoxic reaction may occur

Following days to weeks

Healing, peeling, and pigment changes

Following months

Persistent hyperpigmentation in some cases

Clinical implication

A patient examined soon after psoralen exposure may have normal skin despite subsequently developing substantial burns.

Absence of visible skin injury during an initial emergency assessment does not exclude delayed phototoxicity.


9. Diagnosis

Diagnosis is primarily clinical.

Exposure history

Determine whether exposure involved oral methoxsalen, another medicinal psoralen, a topical phototherapy preparation, or a naturally occurring plant product.

Ask about the quantity, timing, route of exposure, and subsequent sunlight or artificial UVA exposure.

For phototherapy patients, establish the timing of the medication relative to irradiation, the treatment duration, and whether an excessive dose or equipment error occurred.

Skin examination

Assess the distribution, depth, and extent of injury.

Phototoxic burns are often sharply limited to sun-exposed or plant-contaminated areas.

Differential diagnosis

Consider:

  • Ordinary sunburn.
  • Thermal or chemical burns.
  • Allergic contact dermatitis.
  • Other medication-induced phototoxicity.
  • Photoallergic dermatitis.
  • Porphyria-related photosensitivity.
  • Bullous skin disorders.
  • Infection or cellulitis.

In children, patterned phytophotodermatitis can occasionally resemble inflicted injury. A careful clinical and exposure history is necessary before drawing conclusions.


10. Investigations

Mild exposure

No routine laboratory investigations are necessary in uncomplicated cases of limited skin involvement.

Severe skin injury

Electrolytes, creatinine, and other tests may be appropriate when extensive burns cause dehydration or systemic complications.

Oral overdose

Routine serum psoralen concentrations are not generally available and do not guide emergency treatment.

After intentional or uncertain overdose, evaluate possible coingestants as clinically indicated.

Burn assessment

Extensive blistering should be assessed for total body surface area, depth, and functional impact.

Ophthalmologic assessment

Eye examination is appropriate for ocular exposure, persistent eye pain, visual symptoms, or other specific concerns.


11. Immediate treatment

Avoiding additional UVA exposure is the most important intervention.

Oral psoralen ingestion

Move the patient to an environment protected from sunlight and other significant UVA sources.

Use appropriate protective clothing and UVA-blocking eyewear.

Consult a poison control center or medical toxicologist for substantial ingestion.

Plant or topical skin exposure

Wash affected skin promptly with soap and water to remove residual sap, juice, or topical preparation.

Remove contaminated clothing.

Early washing may reduce ongoing exposure but cannot reverse photochemical damage that has already occurred.

Eye exposure

Irrigate the eye promptly with water or saline.

Arrange assessment when pain, redness, visual disturbance, or other concerning findings persist.


12. Light avoidance and ocular protection

After oral methoxsalen

U.S. methoxsalen prescribing information directs patients to:

  • Avoid sunlight, including sunlight through windows or cloud cover, for at least 8 hours after ingestion.
  • Wear suitable UVA-blocking wraparound sunglasses for 24 hours after ingestion during daylight exposure.
  • Avoid sunbathing for 48 hours following PUVA treatment.

These are standard labeled precautions for therapeutic use.

After overdose

A substantial or uncertain overdose warrants more conservative photoprotection than routine treatment.

A protected indoor environment and avoidance of significant UVA exposure for at least 24 hours, with longer precautions according to the formulation, dose, and toxicology advice, may be appropriate.

Ocular protection remains essential.

Practical distinction

Protection of the eyes and protection of the skin are separate requirements with different durations.

Ordinary tinted sunglasses are not necessarily adequate; the glasses must provide reliable UVA blocking and sufficient side coverage.


13. Gastrointestinal decontamination

Induced vomiting

Do not induce vomiting with ipecac or other methods.

Although some older methoxsalen labels still advise induced emesis after overdose, this recommendation is inconsistent with contemporary poisoning management.

Gastric lavage

Routine gastric lavage is not recommended.

Activated charcoal

A single dose of activated charcoal may be considered after a substantial recent oral ingestion, provided the airway is protected.

However, evidence supporting a meaningful clinical benefit specifically for psoralen poisoning is limited.

Activated charcoal should not be administered automatically after every ingestion.

Antidote

There is no specific antidote for psoralen poisoning.


14. Management of phototoxic skin injury

Mild reactions

Use cool compresses, appropriate moisturizers, gentle skin cleansing, and analgesics when needed.

Avoid additional UVA exposure.

Inflammatory lesions

Topical corticosteroids may reduce inflammation in selected cases.

Treatment strength and duration should reflect the affected area and clinical severity.

Blistering

Protect blistered areas from further trauma.

Use suitable nonadherent dressings when needed.

Do not routinely rupture intact blisters.

Severe burns

Patients with extensive blistering or deep tissue injury may require specialized burn care.

Assess hydration, pain control, wound infection risk, and functional impairment.

Antibiotics

Antibiotics are not routinely indicated for sterile phototoxic burns.

Treat secondary bacterial infection when clinically suspected or confirmed.

Recovery

The active inflammatory phase generally resolves over days to weeks.

Postinflammatory hyperpigmentation may persist long after the skin has otherwise healed.


15. Long-term risks of therapeutic PUVA

The risk of chronic toxicity differs substantially from the risk after a single accidental ingestion.

Skin cancer

Repeated PUVA exposure is associated with an increased risk of cutaneous squamous cell carcinoma, particularly after high cumulative numbers of treatments.

Risk may persist long after therapy ends.

Basal cell carcinoma and melanoma risks have also been investigated, with associations influenced by cumulative exposure, patient characteristics, and other treatments.

Photoaging

Repeated treatment can contribute to skin wrinkling, dryness, freckling, altered pigmentation, and loss of elasticity.

Eye protection

Appropriate UVA-blocking goggles during treatment and eyewear after oral psoralen administration are important protective measures.

Follow-up

Patients with substantial cumulative PUVA exposure may require long-term dermatologic surveillance for skin cancer.

These risks are related mainly to repeated psoralen-plus-UVA treatment, not ordinary food consumption or a single minor exposure.


16. Interactions and contraindications

Other photosensitizing medications

Additional medications may increase phototoxic or photoallergic reactions.

Examples include selected tetracyclines, fluoroquinolones, thiazide diuretics, phenothiazines, and other photosensitizing drugs.

The risk varies substantially by specific agent.

Photosensitive diseases

Certain porphyrias, lupus-related photosensitivity, xeroderma pigmentosum, and other conditions may make PUVA unsuitable.

Skin cancer history

A history of melanoma or invasive squamous cell carcinoma is a major concern and is included among contraindications in oral methoxsalen labeling.

Eye disorders

Patients without a natural lens, and those with other high-risk ocular conditions, require particular caution.

Pregnancy

Methoxsalen and PUVA are generally avoided during pregnancy because of limited reproductive safety data and the availability of other therapies.

Clinical practice

PUVA should be administered under dermatologic supervision after evaluating contraindications, medication interactions, and the cumulative phototherapy history.


17. Observation and disposition

Minor plant-associated contact

Limited phytophotodermatitis may be managed as an outpatient when pain is controlled, skin involvement is small, and there are no ocular or other complications.

The patient must understand that visible injury may develop after a delay.

Significant oral exposure

Substantial ingestion of a pharmaceutical psoralen requires poison-center assessment and individualized observation.

A normal initial examination does not establish that later UVA-associated injury cannot occur.

Hospital admission

Hospitalization may be appropriate for extensive blistering, severe pain, dehydration, significant ocular injury, or other complications requiring inpatient treatment.

Discharge criteria

Discharge may be appropriate when the patient is clinically stable, the anticipated risk has been assessed, and reliable UVA avoidance and follow-up can be arranged.

A fixed emergency department observation period cannot replace effective light-protection instructions.


18. Prevention and patient education

During PUVA treatment

Take psoralen medications only according to the phototherapy clinic’s instructions.

Do not increase the dose or extend UVA exposure independently.

Avoid tanning beds and unplanned sun exposure.

Use the recommended eye protection and protective clothing.

Report significant redness or burning before any subsequent PUVA session.

During gardening and food preparation

Wash skin promptly after contact with lime juice, fig sap, parsnip, hogweed, or other known photosensitizing plants.

Use gloves and protective clothing when handling hazardous plant material.

Avoid sunlight on contaminated skin.

Household and occupational safety

Workers handling large quantities of furocoumarin-containing plants may benefit from protective gloves, sleeves, face protection, and work-practice changes.

Children

Store pharmaceutical psoralens securely.

Children who develop patterned blistering after outdoor activities may need assessment for plant-associated phototoxicity.


19. Clinical pitfalls

Pitfall

Contemporary correction

Assuming psoralens are highly toxic without light exposure

Their principal serious toxicity requires UVA activation

Assuming normal skin immediately after exposure excludes injury

Burns may emerge 24–48 hours later

Confusing phytophotodermatitis with allergy

It is typically a direct phototoxic reaction

Assuming sunlight through windows is harmless

UVA can penetrate ordinary window glass

Advising simple tinted glasses

Reliable UVA-blocking wraparound eyewear is needed

Using one duration for all photoprotection

Eye and skin protection have different labeled intervals

Inducing vomiting after oral overdose

Do not induce vomiting

Routinely administering charcoal

Use only after individualized assessment

Discharging without delayed-burn precautions

Skin injury may peak at 48–72 hours

Giving antibiotics solely for blistering

Phototoxic burns are not inherently bacterial infections

Assuming food exposure and medicinal PUVA carry identical risks

Concentration, route, and UVA dose determine risk

Ignoring chronic PUVA exposure

Repeated treatment increases skin-cancer risk

Treating severe burns like mild sunburn

Extensive injury may require specialized burn management


Key clinical conclusions

Psoralen poisoning is primarily a photosensitization problem in which the combination of a photoreactive chemical and UVA exposure causes tissue damage.

The greatest immediate danger is delayed, potentially severe skin injury following excessive UVA exposure.

Early washing of contaminated skin, prompt UVA avoidance, and appropriate eye protection are fundamental.

There is no specific antidote. Treatment is supportive and directed toward the severity of skin or ocular injury.

Long-term therapeutic PUVA exposure also requires attention to cumulative skin-cancer risk.


Image description
0 Comments